Eliem ends ETX-810 program after unambiguous failure

3 August 2022

Eliem Therapeutics (Nasdaq: ELYM), an Anglo-American biotech focused on developing therapies for neuronal excitability disorders, has reported results from its Phase IIa trial investigating ETX-810 for the treatment of lumbosacral radicular pain (LSRP).

ETX-810 is a novel chemical entity prodrug of the bioactive lipid palmitoylethanolamide that was evaluated in two Phase IIa clinical trials, one in subjects with diabetic peripheral neuropathic pain (DPNP) and one in subjects with LSRP.

In the Phase IIa clinical trial in LSRP, ETX-810 did not achieve statistically-significant separation from placebo on the trial’s primary endpoint.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK